173 related articles for article (PubMed ID: 19555390)
1. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
[TBL] [Abstract][Full Text] [Related]
2. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4.
Kato-Nakano M; Suzuki M; Kawamoto S; Furuya A; Ohta S; Nakamura K; Ando H
Anticancer Res; 2010 Nov; 30(11):4555-62. PubMed ID: 21115905
[TBL] [Abstract][Full Text] [Related]
3. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
[TBL] [Abstract][Full Text] [Related]
4. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.
Yuan X; Lin X; Manorek G; Kanatani I; Cheung LH; Rosenblum MG; Howell SB
Mol Cancer Ther; 2009 Jul; 8(7):1906-15. PubMed ID: 19567823
[TBL] [Abstract][Full Text] [Related]
5. Generation of specific monoclonal antibodies against the extracellular loops of human claudin-3 by immunizing mice with target-expressing cells.
Ando H; Suzuki M; Kato-Nakano M; Kawamoto S; Misaka H; Kimoto N; Furuya A; Nakamura K
Biosci Biotechnol Biochem; 2015; 79(8):1272-9. PubMed ID: 25744656
[TBL] [Abstract][Full Text] [Related]
6. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.
Shang X; Lin X; Alvarez E; Manorek G; Howell SB
Neoplasia; 2012 Oct; 14(10):974-85. PubMed ID: 23097631
[TBL] [Abstract][Full Text] [Related]
7. C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.
Gao Z; Xu X; McClane B; Zeng Q; Litkouhi B; Welch WR; Berkowitz RS; Mok SC; Garner EI
Clin Cancer Res; 2011 Mar; 17(5):1065-74. PubMed ID: 21123456
[TBL] [Abstract][Full Text] [Related]
8. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
9. Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.
Song JX; Cao WL; Li FQ; Shi LN; Jia X
Med Oncol; 2012 Dec; 29(4):2923-31. PubMed ID: 22198696
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
11. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
12. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
14. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
15. Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.
Doberstein K; Harter PN; Haberkorn U; Bretz NP; Arnold B; Carretero R; Moldenhauer G; Mittelbronn M; Altevogt P
Int J Cancer; 2015 Mar; 136(5):E326-39. PubMed ID: 25230579
[TBL] [Abstract][Full Text] [Related]
16. Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo.
Ando H; Matsushita T; Wakitani M; Sato T; Kodama-Nishida S; Shibata K; Shitara K; Ohta S
Biol Pharm Bull; 2008 Sep; 31(9):1739-44. PubMed ID: 18758069
[TBL] [Abstract][Full Text] [Related]
17. Visualization of a novel human monoclonal antibody against Claudin-3 for targeting ovarian cancer.
Oh S; Yang H; Oh HR; Seo MR; Lee CH; Kim YH; Choi JY; Kim NY; Cheon GJ; Kang KW; Shin YK; Youn H
Nucl Med Biol; 2022; 114-115():135-142. PubMed ID: 35501237
[TBL] [Abstract][Full Text] [Related]
18. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas.
Rangel LB; Agarwal R; D'Souza T; Pizer ES; Alò PL; Lancaster WD; Gregoire L; Schwartz DR; Cho KR; Morin PJ
Clin Cancer Res; 2003 Jul; 9(7):2567-75. PubMed ID: 12855632
[TBL] [Abstract][Full Text] [Related]
19. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
Kato Y; Mizuno T; Yamada S; Nakamura T; Itai S; Yanaka M; Sano M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):218-223. PubMed ID: 30362926
[TBL] [Abstract][Full Text] [Related]
20. Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma.
Bosslet K; Döring N; Seemann G; Schulz G; Sedlacek HH
Int J Cancer Suppl; 1988; 2():85-8. PubMed ID: 3162450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
